INVESTORS

Press Releases

Precision BioSciences Announces its Addition to the Russell Microcap® Index
July 1, 2024
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 1, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,...
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
June 20, 2024
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 20, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,...
Precision BioSciences to Participate in Upcoming June Investor Conferences
May 30, 2024
DURHAM, N.C. --(BUSINESS WIRE)--May 30, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,...
Precision BioSciences to Report First Quarter Results on May 13, 2024
May 7, 2024
DURHAM, N.C. --(BUSINESS WIRE)--May 7, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,...
Displaying 1 - 10 of 25

Investors

Investor Tools